Venmax drugs & pharmaceuticals Limited has informed BSE Limited about its exemption from submitting the Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The notification was filed on April 14, 2026, citing regulatory provisions that provide relief to smaller listed entities.

Regulatory Exemption Details

The exemption is granted under Regulation 15(2)(b) of SEBI (LODR) Regulations 2015, which specifies that corporate governance provisions under Regulation 24A do not apply to certain categories of listed entities. The regulation provides clear thresholds for exemption based on company size and financial parameters.

Company's Compliance Status

Venmax Drugs & Pharmaceuticals Limited falls within the exemption parameters as its paid-up capital and turnover remain below the specified threshold limits under Regulation 15(2) of SEBI (LODR) Regulations 2015. This positioning allows the company to operate without the additional compliance burden of annual secretarial reporting requirements.

The communication was made in reference to SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 08, 2019, which provides detailed guidelines regarding the submission of Annual Secretarial Compliance Reports. The circular outlines the framework for compliance requirements and exemption criteria for listed entities.

Official Communication

Company Secretary and Compliance Officer Priyanka Agarwal signed the official communication to BSE Limited's Corporate Relationship Department. The notification ensures proper disclosure to the stock exchange regarding the company's compliance status and regulatory positioning.

The company requested BSE Limited to take note of this exemption status in their records, ensuring proper documentation of the regulatory relief applicable to the entity for the specified financial year.

Venmax drugs & pharmaceuticals Limited has submitted its quarterly compliance certificate to BSE Limited, confirming adherence to SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The submission was made on April 14, 2026, as part of the company's regulatory obligations.

Regulatory Compliance Details

The compliance certificate was filed pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This regulation mandates companies to provide confirmation regarding their compliance with depositories-related requirements on a quarterly basis.

Certificate Issuance and Verification

The compliance certificate was issued by CIL Securities Limited, which serves as the Registrar and Share Transfer Agent (RTA) for Venmax Drugs & Pharmaceuticals Limited. CIL Securities Limited confirmed that securities received from Depository Participants for dematerialization during the quarter ended March 31, 2026, were properly processed and confirmed to the depositories.

The RTA also verified that:

• Securities comprised in the certificates have been listed on stock exchanges where the company's earlier issued securities are listed
• Security certificates received for dematerialization have been mutilated and cancelled after due verification
• Names of depositories have been substituted in the Register of Members as registered owners within the stipulated time period

Corporate Communication

The submission was made by Priyanka Agarwal, Company Secretary & Compliance Officer of Venmax Drugs & Pharmaceuticals Limited. The communication was digitally signed and timestamped on April 14, 2026, at 12:29:13 +05'30', ensuring proper authentication and record-keeping.

Company Background

Venmax Drugs & Pharmaceuticals Limited, formerly known as Yenkey Drugs & Pharmaceuticals Ltd, operates from Nama Chemicals Industries in Hyderabad, Telangana. The company maintains its registered office at IDA Cherlapally and continues to fulfill its regulatory obligations as a listed entity on Indian stock exchanges.